Manufacturing

  • PharmaVoice 100 gene cell
    Image attribution tooltip
    Photo illustration: Industry Dive; Getty Images via Getty Images
    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers

    Leaders molding the cutting-edge cell and gene therapy field into tomorrow's cures.

    By • Oct. 30, 2024
  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Backlash builds against Novo’s Catalent takeover

    Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.

    By • Oct. 30, 2024
  • test tube gene Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Cell and gene therapies

    How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

    By PharmaVoice staff
  • Dengue vax
    Image attribution tooltip
    Buda Mendes via Getty Images
    Image attribution tooltip

    Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?

    As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.

    By Alexandra Pecci • Oct. 23, 2024
  • Katelyn Jetelina
    Image attribution tooltip
    Permission granted by Katelyn Jetelina
    Image attribution tooltip
    Q&A

    ‘It’s been hard to watch.’ A noted epidemiologist talks H5N1 and the U.S.’s fragmented response.

    Katelyn Jetelina, well known for her newsletter “Your Local Epidemiologist,” digs into the H5N1 outbreak, the public health response and what’s next for vaccinations.

    By Alexandra Pecci • Oct. 9, 2024
  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Novo plans new plant as it races to meet drug demand

    The new factory, which Novo is committing some $220 million to build, will supply raw materials for the company’s chronic disease medicines.

    By Ned Pagliarulo • Aug. 19, 2024
  • Robot arm DNA
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Can robots break the cell therapy bottleneck?

    A partnership between the cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could bring the manufacturing bottleneck under control, the CEOs said.

    By • May 29, 2024
  • ftc federal trade commission
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    FTC request may signal trouble for Novo/Catalent deal

    As Novo Nordisk aims to secure its manufacturing foothold for GLP-1s, regulators are digging for clues of anti-competitive behavior.

    By Kelly Bilodeau • May 29, 2024
  • Pittsburg
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 up-and-coming US biotech hotspots

    These three U.S. cities are putting themselves on the biotech map as unsung hubs of the industry.

    By Alexandra Pecci • May 21, 2024
  • Eli Lilly CEO Dave Ricks Speaks At The Economic Club Of New York
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    As Lilly surges, headwinds against its weight loss drugs are growing

    After missing analysts’ earnings expectations for Mounjaro sales in the first quarter due to overwhelming demand, Lilly is also dealing with a legal loss and incoming pricing questions from lawmakers.

    By • May 15, 2024
  • Robert Califf
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    As drug shortages reach record highs, regulators float next steps

    With many chemo and ADHD drugs stuck in stubborn shortages, several agencies are looking for new solutions to boost supplies.

    By Kelly Bilodeau • May 6, 2024
  • Close-Up Of Pipette Dripping Chemical In Test Tube At Laboratory
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    FDA’s new diagnostic rules draw pharma criticism

    Tests frequently used in clinical trials will soon be regulated like medical devices — with some exceptions.

    By • May 6, 2024
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    As Lilly and BMS invest in manufacturing, demand for drugs still outweighs supply

    From popular weight loss drugs to lifesaving cancer therapies, recent pharma deals show the industry is doubling down on manufacturing capacity to meet demand.

    By • April 25, 2024
  • U.S. President Joe Biden
    Image attribution tooltip
    Alex Wong/Getty Images via Getty Images
    Image attribution tooltip
    Q&A

    Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake

    A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.

    By • March 14, 2024
  • House Energy And Commerce Committee Chair Cathy Rodgers stern look
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    After ‘tragic’ bacterial outbreak, lawmakers press FDA to step up foreign inspections

    Impatience to fix long-held challenges to overseas drug facility inspections is growing on Capitol Hill.

    By • March 1, 2024
  • One of Kite Pharma's buildings.
    Image attribution tooltip
    Courtesy of Kite Pharma, Inc.
    Image attribution tooltip

    Kite’s next-gen CAR-T aims include quicker production and more disease targets

    While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

    By Kelly Bilodeau • Feb. 20, 2024
  • vials
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 questions hanging over the Novo-Catalent deal

    As backlash builds for the recently announced matchup, critical questions remain over its impact.

    By Kelly Bilodeau • Feb. 13, 2024
  • Helen Sabzevari header
    Image attribution tooltip
    Permission granted by Precigen
    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Helen Sabzevari, an immunotherapy pioneer

    Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

    By • Oct. 27, 2023
  • spilling cough syrup
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 recent FDA adcomm rejections — and why they matter

    Decisions that could spell doom for drugs in development and already on the shelves.

    By • Sept. 29, 2023
  • CSL Seqirus influenza vaccine being prepared in the lab.
    Image attribution tooltip
    Permission granted by CSL Seqirus
    Image attribution tooltip

    Finding the right flu vaccine is hard. Getting people to take it is harder.

    Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.

    By • Aug. 30, 2023
  • Pills of varying colors lay against a blue background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Drug shortages: The ‘fundamental problem’ that has pharma’s top regulator ‘fired up’

    FDA Commissioner Robert Califf suggested larger reforms are needed to bolster the generic drug industry and prevent future medication shortages. 

    By Karissa Waddick • Aug. 25, 2023
  • vaccine vial
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s rare disease rush

    Biogen’s acquisition of Reata Pharmaceuticals is the latest in a string of high-dollar rare disease deals over the last few months. What does it mean for industry?

    By , Karissa Waddick • Aug. 14, 2023
  • An AbbVie sign is seen on a building at the pharmaceutical company's U.S. headquarters.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    Biosimilar makers split strategies in bid to take on top-selling Humira

    In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.

    By Jonathan Gardner • July 26, 2023
  • Pharma vials
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A

    As biologics boom, here’s how manufacturers are keeping up

    Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.

    By • July 19, 2023
  • two lab techs pipette
    Image attribution tooltip
    Adene Sanchez via Getty Images
    Image attribution tooltip

    Boosting the cell and gene therapy workforce with a skilled, localized approach

    Experts provide a roadmap for how the industry can work with academia to ensure a robust talent pipeline for the burgeoning field.

    By Karissa Waddick • June 15, 2023
  • Money squeeze
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Drugmakers feel the squeeze as cost pressures mount

    Supply chain challenges have eased — but now inflation and manufacturing complexity are triggering a new sense of urgency to bring costs down.

    By Kelly Bilodeau • June 5, 2023